Martine Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), recently completed a series of equity transactions on June 18, 2026. The activities involved the disposal of common stock valued at approximately $5.13 million. These sales were executed through a pre-arranged 10b5-1 trading plan that Ms. Rothblatt established on November 7, 2025.
The CEO disposed of a total of 9,500 shares of United Therapeutics common stock during this period. The transactions were executed at prices ranging from $533.64 to $552.72 per share. Prior to the sale, Ms. Rothblatt acquired the identical number of shares through the exercise of stock options on the same day. These options were exercised at a price of $146.03 per share, representing a total value of approximately $1.39 million.
Following these transactions, Ms. Rothblatt directly holds 40,513 shares of United Therapeutics common stock. Her indirect holdings include 166 shares held by her spouse and an aggregate of 628,049 shares held across various family trusts. Ms. Rothblatt also retains 2,910 stock options.
These corporate governance updates coincide with recent financial and operational developments at United Therapeutics. The company reported first-quarter revenue of $781.5 million, which fell short of the analyst consensus estimate of $797.4 million. Tyvaso revenues were $457.5 million, below the expected $478.6 million, and net income was reported at $274.9 million, missing the consensus estimate of $320.5 million.
In pipeline news, United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint. The study, published in the New England Journal of Medicine, showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events.
Additionally, United Therapeutics is collaborating with Varda Space Industries to explore microgravity-based pharmaceutical processing for treatments targeting rare pulmonary diseases. This partnership will involve using Varda’s orbital manufacturing platform to improve the stability and delivery characteristics of therapeutic compounds.
Analyst perspectives on United Therapeutics present mixed views. Analyst firm TD Cowen reiterated a Buy rating on United Therapeutics, maintaining a price target of $675.00. Meanwhile, BTIG maintained a Neutral rating on the company following the first-quarter earnings miss. According to InvestingPro analysis, United Therapeutics is currently overvalued relative to its Fair Value. The company maintains a P/E ratio of 19.87 with a market cap of $22.84 billion.